Patent ID: 8530159
Filing Date: 2013-09-10
Classification: A61P,C12Q

Abstract:
1. A method of predicting chemotherapy treatment failure risk in a subject with acute myeloid leukemia (AML), comprising: a) obtaining a test sample from subject having, or suspected of having AML, wherein the sample is extracted from at least one of: blood, bone marrow, and tissue suspected of having leukemic cells, b) measuring the level of miR-29 gene product in the test sample by conducting laboratory analysis of the sample so as to obtain physical data regarding the expression level of miR-29 gene product in the sample, c) comparing the level of miR-29 gene product in the test sample relative to a control level of miR-29 gene product, and d) predicting the subject's chemotherapy treatment failure risk, wherein, if the level of miR-29 gene product in the test sample is low relative to the control level of miR-29 gene product, the subject is predicted to have a high chemotherapy treatment failure risk.